DeoBioSciences (DBS) is a stealth mode, R&D stage, virtual biotech developing a cancer drug, based on a naturally occurring compound, that selectively kills both early and advanced stage cancer cells from humans and, potentially, dogs and cats as well.
We are reverse engineering the drug from anecdotal data and reports of human efficacy and safety from bioprospecting sources and also corroborating studies involving molecular homologues in humans and animals that further affirmed safety and efficacy projections. So far, our pre-clinical lab results have corroborated and met all our...
- Min investment
- Days Left
- Security Type
Common stock is a security that represents ownership in a corporation.
- March 24, 2021
- April 30, 2021
- Deal Structure
Price Per Share: $50.00
- Pre-Clinical Drug Manufacturing 27.1%
- Pre-Clinical animal trials/studies 22.9%
- Payroll & Benefits 31.4%
- R&D consultants/contractors 8.2%
- Admin. Operations, Rent, IP & Legal, Miscellaneous 5.5%
- Intermediary fees 4.9%
CrowdLustro Research Report
Use of Proceeds
Dr. H.G. Schmidt
Lead Cancer Research Scientist @ Cornell University
Dr. C.P. Wellstone
Veterinary Clinical Trial Lead Strategist and Scientist
No reports have been submittedBecome a Reporter